Literature DB >> 30271520

BIOMARKER CHANGE-POINT ESTIMATION WITH RIGHT CENSORING IN LONGITUDINAL STUDIES.

Xiaoying Tang1, Michael I Miller2, Laurent Younes2.   

Abstract

We consider in this paper a statistical two-phase regression model in which the change point of a disease biomarker is measured relative to another point in time, such as the manifestation of the disease, which is subject to right-censoring (i.e., possibly unobserved over the entire course of the study). We develop point estimation methods for this model, based on maximum likelihood, and bootstrap validation methods. The effectiveness of our approach is illustrated by numerical simulations, and by the estimation of a change point for amygdalar atrophy in the context of Alzheimer's disease, wherein it is related to the cognitive manifestation of the disease.

Entities:  

Keywords:  Change-point estimation; medical imaging; right censoring

Year:  2017        PMID: 30271520      PMCID: PMC6157754          DOI: 10.1214/17-AOAS1056

Source DB:  PubMed          Journal:  Ann Appl Stat        ISSN: 1932-6157            Impact factor:   2.083


  30 in total

1.  Cognitive and neural mechanisms of emotional memory.

Authors:  S Hamann
Journal:  Trends Cogn Sci       Date:  2001-09-01       Impact factor: 20.229

Review 2.  Comparative aspects of amygdala connectivity.

Authors:  Joseph L Price
Journal:  Ann N Y Acad Sci       Date:  2003-04       Impact factor: 5.691

3.  Amygdala cell loss and atrophy in Alzheimer's disease.

Authors:  S A Scott; S T DeKosky; D L Sparks; C A Knox; S W Scheff
Journal:  Ann Neurol       Date:  1992-10       Impact factor: 10.422

Review 4.  Hamiltonian Systems and Optimal Control in Computational Anatomy: 100 Years Since D'Arcy Thompson.

Authors:  Michael I Miller; Alain Trouvé; Laurent Younes
Journal:  Annu Rev Biomed Eng       Date:  2015-11-04       Impact factor: 9.590

5.  The diffeomorphometry of regional shape change rates and its relevance to cognitive deterioration in mild cognitive impairment and Alzheimer's disease.

Authors:  Xiaoying Tang; Dominic Holland; Anders M Dale; Laurent Younes; Michael I Miller
Journal:  Hum Brain Mapp       Date:  2015-02-03       Impact factor: 5.038

6.  Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease.

Authors:  C R Jack; R C Petersen; Y C Xu; S C Waring; P C O'Brien; E G Tangalos; G E Smith; R J Ivnik; E Kokmen
Journal:  Neurology       Date:  1997-09       Impact factor: 9.910

7.  Amygdala atrophy is prominent in early Alzheimer's disease and relates to symptom severity.

Authors:  Stéphane P Poulin; Rebecca Dautoff; John C Morris; Lisa Feldman Barrett; Bradford C Dickerson
Journal:  Psychiatry Res       Date:  2011-09-14       Impact factor: 3.222

8.  Local amygdala structural differences with 3T MRI in patients with Alzheimer disease.

Authors:  E Cavedo; M Boccardi; R Ganzola; E Canu; A Beltramello; C Caltagirone; P M Thompson; G B Frisoni
Journal:  Neurology       Date:  2011-02-22       Impact factor: 9.910

9.  2015 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2015-03       Impact factor: 21.566

10.  Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging.

Authors:  Henry Rusinek; Susan De Santi; Dina Frid; Wai-Hon Tsui; Chaim Y Tarshish; Antonio Convit; Mony J de Leon
Journal:  Radiology       Date:  2003-12       Impact factor: 11.105

View more
  1 in total

1.  Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer's Disease.

Authors:  Laurent Younes; Marilyn Albert; Abhay Moghekar; Anja Soldan; Corinne Pettigrew; Michael I Miller
Journal:  Front Aging Neurosci       Date:  2019-04-02       Impact factor: 5.750

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.